clinical 1,226 words KG: Lithium for Parkinson's Disease - SUNY Buffalo Trial (NCT06339034) 2026-03-27
kind:clinical-trialsection:clinical-trialsstate:published
Contents

Lithium for Parkinson's Disease - SUNY Buffalo Trial (NCT06339034)

Knowledge Graph

Related Hypotheses (3)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52

Related Analyses (13)

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed

Related Experiments (30)

Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40

Knowledge Graph (2 edges)

Lithium for Parkinson's Disease - SUNY Buffalo Trial (NCT06339034) references GFAP
Lithium for Parkinson's Disease - SUNY Buffalo Trial (NCT06339034) references BDNF